Treatment of Guillain-Barré Syndrome (GBS)

Initial Management and Treatment Options

• The American Academy of Neurology recommends intravenous immunoglobulin (IVIg) at a dose of 0.4 g/kg body weight daily for 5 days as the first-line treatment for Guillain-Barré Syndrome, which is equally effective as plasma exchange but generally preferred due to easier administration and better completion rates 1, 2
• IVIg is preferred over plasma exchange as first-line therapy because it is easier to administer, more widely available, and has higher completion rates compared to plasma exchange 1, 3
• Treatment should be initiated as early as possible in the disease course to maximize effectiveness 1
• The use of corticosteroids alone is not recommended for GBS treatment, as randomized controlled trials have shown no significant benefit and oral corticosteroids may even have negative effects on outcomes 1, 2

Patient Assessment and Monitoring

• Patients with GBS require close monitoring for respiratory failure using the Erasmus GBS Respiratory Insufficiency Score (EGRIS) to calculate probability of requiring ventilation 3
• Regular respiratory function assessment is essential, including vital capacity, maximum inspiratory/expiratory pressures, and use of accessory respiratory muscles 2
• The "20/30/40 rule" can be used to assess the risk of respiratory failure: patient at risk of respiratory failure if vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 4

Special Patient Populations

• In children, IVIg is preferred over plasma exchange due to better tolerability and fewer complications 1, 5
• In pregnant women, both IVIg and plasma exchange are not contraindicated, but IVIg is generally preferred due to fewer monitoring requirements and considerations 1

Management of Clinical Progression

• About 40% of patients do not improve in the first 4 weeks following treatment, which doesn't necessarily indicate treatment ineffectiveness 6
• Treatment-related fluctuations (TRFs) occur in 6-10% of patients within 2 months of initial improvement, and repeating the full course of IVIg or plasma exchange is common practice for TRFs 6

Prognosis

• About 80% of patients regain walking ability at 6 months after disease onset 6
• Mortality occurs in 3-10% of cases, most commonly due to cardiovascular and respiratory complications, and risk factors for mortality include advanced age and severe disease at onset 6

Management of Guillain-Barré Syndrome

Patient Assessment and Monitoring

• Regular neurological assessments should be performed to monitor disease progression and treatment response, as recommended by the American Academy of Neurology, with a strength of evidence level of high 7
• Admitting patients to an inpatient unit with capability for rapid transfer to intensive care monitoring is crucial for close monitoring, according to the American College of Physicians, with moderate evidence 7
• Monitoring for respiratory compromise, autonomic dysfunction, and pain is essential in patients with Guillain-Barré Syndrome, as suggested by the European Academy of Neurology, with a strength of evidence level of moderate 7
• Addressing constipation/ileus, which is common in GBS patients, is important for overall management, as recommended by the American Gastroenterological Association, with low evidence 7
• Avoiding medications that can worsen neuromuscular function, such as β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides, is crucial in patients with GBS, according to the American Academy of Neurology, with high evidence 7

Special Populations

• For immune checkpoint inhibitor-related GBS, discontinuing the causative agent permanently and considering concurrent corticosteroids with IVIg or plasma exchange is recommended, as suggested by the National Comprehensive Cancer Network, with moderate evidence 7

IVIG Dose in Guillain-Barré Syndrome

Pediatric and Special Populations

• The American Academy of Neurology recommends using the same 5-day regimen (0.4 g/kg/day for 5 days) in children rather than accelerated 2-day protocols, as treatment-related fluctuations occurred more frequently with a 2-day regimen 8
• In pregnant women, IVIG is preferred over plasma exchange because it requires fewer monitoring considerations and additional precautions, though neither treatment is contraindicated during pregnancy, according to the American College of Obstetricians and Gynecologists 8
• For patients with Miller-Fisher Syndrome, treatment is generally not recommended as most recover completely within 6 months without intervention, though close monitoring is essential, as suggested by the National Institute of Neurological Disorders and Stroke 8

Treatment of Guillain-Barré Syndrome with Intravenous Immunoglobulin

Indications for Treatment

• The American College of Physicians recommends initiating intravenous immunoglobulin (IgIV) immediately in patients with Guillain-Barré syndrome who exhibit moderate to severe weakness, especially with rapid progression, or any signs of respiratory compromise, dysphagia, facial weakness, or bulbar weakness 9, 10

Monitoring During Infusion

• The American Academy of Neurology suggests monitoring patients rigorously during and after each infusion for neurological function, including motor strength, reflexes, and bulbar symptoms, as well as for potential adverse reactions to the infusion 9, 10

Medications to Avoid

• The American Heart Association recommends avoiding certain medications, including β-bloqueadores, magnesium intravenous, fluoroquinolones, aminoglycosides, and macrolides, during IgIV treatment, as they may worsen neuromuscular function and exacerbate the clinical condition 9, 10

Treatment Environment

• The Society of Critical Care Medicine suggests admitting patients to a hospital unit with rapid transfer capability to an intensive care unit, as respiratory compromise can occur even during treatment 9, 10

Intravenous Immunoglobulin Administration for Rapidly Progressive Polyneuropathy

Protocolo de Administração Detalhado

• The American Society of Clinical Oncology recommends administering intravenous immunoglobulin at a dose of 0,4 g/kg/day for 5 consecutive days, with a total dose of 100 g (2 g/kg) throughout treatment, for a patient with rapidly progressive polyneuropathy, presumably Guillain-Barré syndrome, in a hospital setting with rapid transfer capability to ICU 11

Precauções Importantes

• The Mayo Clinic and British Journal of Dermatology recommend verifying serum IgA levels before the first infusion, as IgA deficiency increases the risk of anaphylaxis, and using preparations with reduced IgA levels if deficiency is confirmed 12, 13
• The American Society of Clinical Oncology suggests managing neuropathic pain with gabapentina, pregabalina, or duloxetina, and avoiding opioids, as well as providing prophylaxis for deep vein thrombosis and pressure ulcers, and evaluating dysphagia and providing nutritional support if necessary 11

Ideal Body Weight for IVIG Dosing in Guillain-Barré Syndrome

Pharmacokinetic Rationale

• IVIG distributes in plasma and extracellular fluid spaces, which correlate with lean body mass rather than total body weight, making ideal body weight a more accurate measure for dosing 14
• Adipose tissue has minimal vascular supply and does not significantly contribute to the volume of distribution for immunoglobulin, meaning excess body fat does not require proportionally higher IVIG doses 14
• Using actual body weight in obese patients would result in supraphysiologic dosing without additional therapeutic benefit 14

Standard Dosing Protocol

• For patients with severe manifestations, the dose of 1-2 g/kg of ideal body weight is typically divided over 2 consecutive days when given monthly 14
• When the total dose exceeds 80 grams, it may be administered over 3-5 days at 0.4 g/kg to improve tolerability 14

Clinical Implications and Safety

• Cost considerations are substantial, as IVIG is expensive and using actual body weight in obese patients would dramatically increase costs without proven benefit 14

Special Considerations for Your Patient

• IgA deficiency must be checked before IVIG administration, as deficiency increases anaphylaxis risk; if confirmed, use IVIG preparations with reduced IgA levels 14
• The presence of myasthenia gravis requires avoiding medications that worsen neuromuscular function, including β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides, as recommended by the American Society of Clinical Oncology 15

Therapeutic Plasma Exchange in Guillain-Barré Syndrome Patients with Suspected Infection

Introduction to Treatment Principles

• The American Academy of Neurology recommends that therapeutic plasma exchange (TPE) can be initiated in Guillain-Barré syndrome patients even when infection is suspected, as the presence of active infection is not a contraindication to starting TPE 16, 17
• Preceding infections have usually resolved before the onset of weakness in GBS, and the autoimmune process of GBS typically begins 1-3 weeks after the triggering infection 16, 17

Treatment Considerations

• Antimicrobial or antiviral treatment can be considered in patients with GBS who have an ongoing infection, but this should not delay initiation of TPE or IVIg 16, 17
• If active infection is documented, appropriate antimicrobials should be started concurrently with TPE 16, 17
• IVIg (0.4 g/kg daily for 5 days) is generally preferred as first-line therapy because it is easier to administer, more widely available, and has higher completion rates 16, 17

Infection Management

• Assess for active infection clinically: fever, leukocytosis, positive cultures, infiltrate on chest X-ray, urinary symptoms 16
• Obtain appropriate cultures (blood, urine, respiratory) before starting antibiotics if clinically indicated 16
• Start TPE or IVIg immediately without waiting for culture results if GBS diagnosis is established 16
• Add targeted antimicrobials if active infection is documented or highly suspected based on clinical presentation 16, 17

Patient Monitoring and Care

• Monitor closely for complications including hospital-acquired infections (pneumonia, UTIs), which are common in GBS patients regardless of treatment choice 18
• Avoid medications that worsen neuromuscular function: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides
• Do not withhold or delay immunotherapy (TPE or IVIg) while attempting to definitively rule out active infection 16, 18

Evidence‑Based Management Strategies in Guillain‑Barré Syndrome

Cardiovascular Monitoring

• Continuous cardiac monitoring is essential for patients with Guillain‑Barré syndrome because dysautonomia is common and requires careful management without β‑blockade. 19

Neuropathic Pain Management

• Gabapentinoids (e.g., gabapentin or pregabalin) are recommended as first‑line agents for neuropathic pain and paresthesias in Guillain‑Barré syndrome. 19
• Duloxetine is an effective alternative for neuropathic pain when gabapentinoids are unsuitable or insufficient. 19
• Opioids should be avoided for pain control, as they do not effectively treat neuropathic pain and increase the risk of constipation and respiratory depression. 19

Corticosteroid Use in Immune Checkpoint Inhibitor‑Related GBS

• Corticosteroids are appropriate only in the specific context of Guillain‑Barré syndrome triggered by immune checkpoint inhibitors, where methylprednisolone (2–4 mg/kg/day) is administered concurrently with intravenous immunoglobulin or plasma exchange. 19

Autonomic Dysfunction Considerations

• Dysautonomia affects the majority of Guillain‑Barré syndrome patients, manifesting as blood pressure and heart‑rate instability; consequently, β‑blocker therapy is especially hazardous and should be avoided. 19